To establish the feasibility of this technique, we collected 27 FT lavages from high‐risk BRCA1/2 mutation carriers, ovarian neoplasm (ON) patients, and control individuals with benign or non‐tubal gynaecological conditions (Figure 1A and B; Supplementary Discussions 1 and 2). The gene discussed is BRCA1; the disease is ovarian neoplasm.